ERBB2 and breast cancer: Given our finding that the top two prognostic signatures can retrospectively predict some common chemotherapeutic outcomes in breast cancer patients (Table 5), we designed an algorithm using the BRmet50 and PMID18271932Sig33 predictors for prospective prediction of taxane-anthracycline sensitivity in individual patients with HER2- breast cancer.